Progress in pathogenesis and drug development of diabetic kidney disease

doi:10.12092/j.issn.1009-2501.2026.06.003

Abstract

Abstract:

Diabetic kidney disease (DKD), a kind of microvascular lesion, is one of the major complications of diabetes. Clinically, it is characterized by proteinuria, mesangial proliferation and thickening of the basement membrane, glomerular sclerosis and fibrosis, and progressive decline of estimated glomerular filtration rate (eGFR), and is recognized as the main cause of end-stage renal disease (ESRD). The pathogenesis of DKD is complex, with genetic factors, abnormal energy metabolism, immunity and inflammation, and hemodynamic abnormalities all participating in and influencing the formation and progression of DKD. The complex molecular mechanism also brings great challenges to the construction of DKD models and the development of new drugs. This article reviews the recent progress in the research of the pathogenesis of DKD, animal disease models, and new drug development, aiming to provide new ideas for the development of drugs for the treatment of DKD.

Key words: diabetic kidney disease, animal model, drug evaluation

CLC Number:

R587.2
R692

Xuewu LIU, Dejian JIANG, Yanhua DU. Progress in pathogenesis and drug development of diabetic kidney disease[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(6): 735-751.

Figures/Tables 7

References 71

1	Owens DR, Gurudas S, Sivaprasad S, et al. IDF diabetes atlas: a worldwide review of studies utilizing retinal photography to screen for diabetic retinopathy from 2017 to 2024 inclusive[J]. Diabetes Res Clin Pract, 2025, 226, 112346. doi: 10.1016/j.diabres.2025.112346
2	Wang Y, Zhang J, Zhao Y, et al. COL4A3 gene variants and diabetic kidney disease in mody[J]. Clin J Am Soc Nephrol, 2018, 13 (8): 1162- 1171.
3	Al-Dabet MM, Shahzad K, Elwakiel A, et al. Reversal of the renal hyperglycemic memory in diabetic kidney disease by targeting sustained tubular p21 expression[J]. Nat Commun, 2022, 13 (1): 5062. doi: 10.1038/s41467-022-32477-9
4	Lu L, Zhu M, Wu Q, et al. Sirt7/HIC1 complex participates in hyperglycaemia-mediated EndMT via modulation of SDC1 expression in diabetic kidney disease and metabolic memory[J]. J Cell Mol Med, 2024, 28 (9): e18336.
5	Xu Z, Jia K, Wang H, et al. METTL14-regulated PI3K/Akt signaling pathway via PTEN affects HDAC5-mediated epithelial-mesenchymal transition of renal tubular cells in diabetic kidney disease[J]. Cell Death Dis, 2021, 12 (1): 32.
6	Mattei AL, Bailly N, Meissner A. DNA methylation: a historical perspective[J]. Trends Genet, 2022, 38 (7): 676- 707.
7	Hill C, Duffy S, Kettyle LM, et al. Differential methylation of telomere-related genes is associated with kidney disease in individuals with type 1 diabetes[J]. Genes (Basel), 2023, 14 (5): 1029.
8	Chen G, Chen H, Ren S, et al. Aberrant DNA methylation of mTOR pathway genes promotes inflammatory activation of immune cells in diabetic kidney disease[J]. Kidney Int, 2019, 96 (2): 409- 420.
9	Jiang Q, Chen H, Wang K, et al. Circ_0054633 silencing suppresses hyperglycemia-induced extracellular matrix accumulation in renal mesangial cells by regulating MiR-136-5p/SMAD3 signaling[J]. Noncoding RNA Res, 2025, 13, 84- 93.
10	Feng X, Zhao J, Ding J, et al. LncRNA Blnc1 expression and its effect on renal fibrosis in diabetic nephropathy[J]. Am J Transl Res, 2019, 11 (9): 5664- 5672.
11	Harvey SJ, Jarad G, Cunningham J, et al. Podocyte-specific deletion of dicer alters cytoskeletal dynamics and causes glomerular disease[J]. J Am Soc Nephrol, 2008, 19 (11): 2150- 2158.
12	Liu J, Xiong Y, Mo H, et al. MicroRNA-29b plays a vital role in podocyte injury and glomerular diseases through inducing mitochondrial dysfunction[J]. Int J Biol Sci, 2024, 20 (12): 4654- 4673.
13	Chen DT, Saltos AN, Rose T, et al. Early adverse event derived biomarkers in predicting clinical outcomes in patients with advanced non-small cell lung cancer treated with immunotherapy[J]. Cancers (Basel), 2023, 15 (9): 2521.
14	Haque T, Cadenas FL, Xicoy B, et al. Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in patients with lower-risk myelodysplastic syndromes[J]. Leuk Res, 2023, 134, 107390.
15	To KKW, Tolu SS, Wang L, et al. HDAC inhibitors: cardiotoxicity and paradoxical cardioprotective effect in ischemia-reperfusion myocardiocyte injury[J]. Semin Cancer Biol, 2025, 113, 25- 38.
16	Li D, Hsu FC, Palmer ND, et al. Multiomics analyses identify akr1a1 as a biomarker for diabetic kidney disease[J]. Diabetes, 2024, 73 (7): 1188- 1195.
17	Du Q, Fu YX, Shu AM, et al. Loganin alleviates macrophage infiltration and activation by inhibiting the MCP-1/CCR2 axis in diabetic nephropathy[J]. Life Sci, 2021, 272, 118808.
18	Fumo P, Kuncio GS, Ziyadeh FN. PKC and high glucose stimulate collagen alpha 1 (IV) transcriptional activity in a reporter mesangial cell line [J]. Am J Physiol, 1994, 267(4 Pt 2): F632-638.
19	Zuo F, Wang Y, Xu X, et al. CCDC92 deficiency ameliorates podocyte lipotoxicity in diabetic kidney disease[J]. Metabolism, 2024, 150, 155724.
20	Zuo FW, Liu ZY, Wang MW, et al. CCDC92 promotes podocyte injury by regulating PA28α/ABCA1/cholesterol efflux axis in type 2 diabetic mice[J]. Acta Pharmacol Sin, 2024, 45 (5): 1019- 1031.
21	Jiang W, Gan C, Zhou X, et al. Klotho inhibits renal ox-LDL deposition via IGF-1R/RAC1/OLR1 signaling to ameliorate podocyte injury in diabetic kidney disease[J]. Cardiovasc Diabetol, 2023, 22 (1): 293.
22	Zhang M, Gao X, Wu J, et al. Oxidized high-density lipoprotein enhances inflammatory activity in rat mesangial cells[J]. Diabetes Metab Res Rev, 2010, 26, 455- 463.
23	Kang HM, Ahn SH, Choi P, et al. Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development[J]. Nat Med, 2015, 21, 37- 46.
24	Jiang WJ, Xu CT, Du CL, et al. Tubular epithelial cell-to-macrophage communication forms a negative feedback loop via extracellular vesicle transfer to promote renal inflammation and apoptosis in diabetic nephropathy[J]. Theranostics, 2022, 12, 324- 339.
25	Kostapanos MS, Florentin M, Elisaf MS. Fenofibrate and the kidney: an overview[J]. Eur J Clin Invest, 2013, 43 (5): 522- 531.
26	Wilson PC, Wu H, Kirita Y, et al. The single-cell transcriptomic landscape of early human diabetic nephropathy[J]. Proc Natl Acad Sci USA, 2019, 116, 19619- 19625.
27	Kim Y, Park CW. Mechanisms of adiponectin action: implication of adiponectin receptor agonism in diabetic kidney disease[J]. Int J Mol Sci, 2019, 20 (7): 1782.
28	Zeng Y, Guo M, Wu Q, et al. Gut microbiota-derived indole-3-propionic acid alleviates diabetic kidney disease through its mitochondrial protective effect via reducing ubiquitination mediated-degradation of SIRT1[J]. J Adv Res, 2025, 73, 607- 630.
29	Zang N, Cui C, Guo X, et al. cGAS-STING activation contributes to podocyte injury in diabetic kidney disease[J]. iScience, 2022, 25 (10): 105145.
30	Liu X, Lu J, Liu S, et al. Huangqi-danshen decoction alleviates diabetic nephropathy in db/db mice by inhibiting PINK1/Parkin-mediated mitophagy[J]. Am J Transl Res, 2020, 12 (3): 989- 998.
31	Engelhart EA, Hoppins S. A catalytic domain variant of mitofusin requiring a wildtype paralog for function uncouples mitochondrial outer-membrane tethering and fusion[J]. J Biol Chem, 2019, 294 (20): 8001- 8014.
32	Yang M, Zhang Q, Luo S, et al. DsbA-L alleviates tubular injury in diabetic nephropathy by activating mitophagy through maintenance of MAM integrity [J]. Clin Sci (Lond), 2023, 137(12): 931-945.
33	Huang Q, Xiong X, Chen S, et al. Asprosin aggravates tubular epithelial cell injury and phenotypic transformation via mitochondrial dynamics disorder mediated by excessive Drp1 SUMOylation in diabetic nephropathy mice [J]. Adv Sci (Weinh), 2025, 12(39): e03259.
34	Wan S, Wan S, Jiao X, et al. Advances in understanding the innate immune-associated diabetic kidney disease[J]. FASEB J, 2021, 35 (2): e21367.
35	Rayego-Mateos S, Rodrigues-Diez RR, Fernandez-Fernandez B, et al. Targeting inflammation to treat diabetic kidney disease: the road to 2030[J]. Kidney Int, 2023, 103 (2): 282- 296.
36	Perez-Gomez MV, Sanchez-Niño MD, Sanz AB, et al. Targeting inflammation in diabetic kidney disease: early clinical trials[J]. Expert Opin Investig Drugs, 2016, 25 (9): 1045- 1058.
37	Tuttle KR, Brosius FC, Adler SG, et al. JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial[J]. Nephrol Dial Transplant, 2018, 33 (11): 1950- 1959.
38	Motwani MP, Flint JD, De Maeyer RP, et al. Novel translational model of resolving inflammation triggered by UV-killed E. coli[J]. J Pathol Clin Res, 2016, 2 (3): 154- 165.
39	Wu L, Liu C, Chang DY, et al. The attenuation of diabetic nephropathy by annexin a1 via regulation of lipid metabolism through the AMPK/PPARα/CPT1b pathway[J]. Diabetes, 2021, 70 (10): 2192- 2203.
40	Li L, Tang W, Zhang Y, et al. Targeting tissue-resident memory CD8⁺ T cells in the kidney is a potential therapeutic strategy to ameliorate podocyte injury and glomerulosclerosis[J]. Mol Ther, 2022, 30 (8): 2746- 2759.
41	Liu C, Qin L, Ding J, et al. Group 2 innate lymphoid cells participate in renal fibrosis in diabetic kidney disease partly via tgf-β1 signal pathway[J]. J Diabetes Res, 2019, 2019, 8512028.
42	Eller K, Kirsch A, Wolf AM, et al. Potential role of regulatory T cells in reversing obesity-linked insulin resistance and diabetic nephropathy[J]. Diabetes, 2011, 60 (11): 2954- 2962.
43	Pedigo CE, Ducasa GM, Leclercq F, et al. Local TNF causes NFATc1-dependent cholesterol-mediated podocyte injury[J]. J Clin Invest, 2016, 126 (9): 3336- 3350.
44	Lee BT, Ahmed FA, Hamm LL, et al. Association of c-reactive protein, tumor necrosis factor-alpha, and interleukin-6 with chronic kidney disease[J]. BMC Nephrol, 2015, 16, 77.
45	Wu R, Liu X, Yin J, et al. IL-6 receptor blockade ameliorates diabetic nephropathy via inhibiting inflammasome in mice[J]. Metabolism, 2018, 83, 18- 24.
46	Nørregaard R, Mutsaers HAM, Frøkiær J, et al. Obstructive nephropathy and molecular pathophysiology of renal interstitial fibrosis[J]. Physiol Rev, 2023, 103 (4): 2827- 2872.
47	Xiao X, Ma B, Dong B, et al. Cellular and humoral immune responses in the early stages of diabetic nephropathy in NOD mice[J]. J Autoimmun, 2009, 32 (2): 85- 93.
48	Imig JD, Ryan MJ. Immune and inflammatory role in renal disease[J]. Compr Physiol, 2013, 3 (2): 957- 976.
49	Nicoloff G, Blazhev A, Petrova C, et al. Circulating immune complexes among diabetic children[J]. Clin Dev Immunol, 2004, 11 (1): 61- 66.
50	Smith MJ, Simmons KM, Cambier JC. B cells in type 1 diabetes mellitus and diabetic kidney disease[J]. Nat Rev Nephrol, 2017, 13, 712- 720.
51	Kobori H, Ozawa Y, Suzaki Y, et al. Young scholars award lecture: intratubular angiotensinogen in hypertension and kidney diseases[J]. Am J Hypertens, 2006, 19, 541- 550.
52	Kim DL, Lee SE, Kim NH. Renal protection of mineralocorticoid receptor antagonist, finerenone, in diabetic kidney disease[J]. Endocrinol Metab (Seoul), 2023, 38 (1): 43- 55.
53	Jia G, Lastra G, Bostick BP, et al. The mineralocorticoid receptor in diabetic kidney disease[J]. Am J Physiol Renal Physiol, 2024, 327 (3): F519- F531.
54	Hsu YH, Zheng CM, Chou CL, et al. Therapeutic effect of endothelin-converting enzyme inhibitor on chronic kidney disease through the inhibition of endoplasmic reticulum stress and the NLRP3 inflammasome[J]. Biomedicines, 2021, 9 (4): 398.
55	Xie H, Zhang X, Peng J, et al. Endothelin-1 down-regulated vascular endothelial growth factor A is involved in trichloroethene-induced kidney injury[J]. Toxicol Ind Health, 2022, 38 (5): 287- 298.
56	Goddard J, Johnston NR, Hand MF, et al. Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: a comparison of selective and combined endothelin receptor blockade[J]. Circulation, 2004, 109 (9): 1186- 1193.
57	Hocher B, Schwarz A, Reinbacher D, et al. Effects of endothelin receptor antagonists on the progression of diabetic nephropathy[J]. Nephron, 2001, 87 (2): 161- 169.
58	Mann JF, Green D, Jamerson K, et al. Avosentan for overt diabetic nephropathy[J]. J Am Soc Nephrol, 2010, 21 (3): 527- 535.
59	Chang JH, Gurley SB. Assessment of diabetic nephropathy in the Akita mouse[J]. Methods Mol Biol, 2012, 933, 17- 29.
60	Wang W, Jiang S, Tang X, et al. Sex differences in progression of diabetic nephropathy in OVE26 type 1 diabetic mice[J]. Biochim Biophys Acta Mol Basis Dis, 2020, 1866 (1): 165589.
61	罗文婷, 唐诗韵, 肖湘, 等. DKD动物模型的研究进展[J]. 成都医学院学报, 2023, 18 (5): 650- 657.
62	钱足平, 陈勇, 冉燕, 等. DKD模型: 动物模型、二维细胞模拟及三维类器官模型[J]. 中国组织工程研究, 2025, 29 (17): 3632- 3640.
63	蒋子健, 陈钇地, 龙莉玲, 等. 扩散峰度成像早期诊断广西巴马小型猪DKD模型的价值[J]. 中华放射学杂志, 2019, 53 (7): 609- 614.
64	Gurley SB, Clare SE, Snow KP, et al. Impact of genetic background on nephropathy in diabetic mice[J]. Am J Physiol Renal Physiol, 2006, 290 (1): F214- 222.
65	Wang Q, Hummler E, Nussberger J, et al. Blood pressure, cardiac, and renal responses to salt and deoxycorticosterone acetate in mice: role of renin genes[J]. J Am Soc Nephrol, 2002, 13 (6): 1509- 1516.
66	Hu H, Hu J, Chen Z, et al. RBBP6-mediated ERRα degradation contributes to mitochondrial injury in renal tubular cells in diabetic kidney disease[J]. Adv Sci (Weinh), 2024, 11 (46): e2405153.
67	张翠香, 洪晓华, 侯金才, 等. 链脲佐菌素DKD大鼠模型肾小球损伤的机制[J]. 中华中医药杂志, 2015, 30 (9): 3087- 3091.
68	Harlan SM, Heinz-Taheny KM, Sullivan JM, et al. Progressive renal disease established by renin-coding adeno-associated virus-driven hypertension in diverse diabetic models[J]. J Am Soc Nephrol, 2018, 29 (2): 477- 491.
69	Bossart M, Wagner M, Elvert R, et al. Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist [J]. Cell Metab, 2022, 34(1): 59-74. e10.
70	李沛城, 冯波. 《中国糖尿病防治指南(2024版)》更新要点解读[J]. 同济大学学报(医学版), 2025, 46 (2): 151- 158.
71	中国中西医结合学会内分泌专业委员会. 渴络欣胶囊治疗糖尿病肾脏疾病临床应用专家共识[J]. 中国中西医结合杂志, 2020, 40 (8): 979- 984.

指标分类	动物模型诊断指标	临床诊断指标
基础性指标	血糖	血糖、糖耐量、胰岛素
肾脏功能性指标	血CRE，尿CRE，血BUN，排尿量，24 h尿微量白蛋白排泄量，尿微量白蛋白和尿肌酐比值（ACR），eGFR或内生肌酐清除率	血CRE，尿CRE，血BUN，排尿量，24 h尿微量白蛋白排泄量，尿微量白蛋白和尿肌酐比值（ACR），eGFR
病理形态学	HE染色、PAS染色、Ⅰ型和Ⅳ胶原染色、电镜观察基底膜厚度	肾脏活检：HE染色、PAS染色、电镜、电镜观察基底膜厚度

指标分类	动物模型诊断指标	临床诊断指标
基础性指标	血糖	血糖、糖耐量、胰岛素
肾脏功能性指标	血CRE，尿CRE，血BUN，排尿量，24 h尿微量白蛋白排泄量，尿微量白蛋白和尿肌酐比值（ACR），eGFR或内生肌酐清除率	血CRE，尿CRE，血BUN，排尿量，24 h尿微量白蛋白排泄量，尿微量白蛋白和尿肌酐比值（ACR），eGFR
病理形态学	HE染色、PAS染色、Ⅰ型和Ⅳ胶原染色、电镜观察基底膜厚度	肾脏活检：HE染色、PAS染色、电镜、电镜观察基底膜厚度

药物名称	药品分类	适应症和研发阶段	作用靶点
厄贝沙坦	化药	上市：原发性高血压，高血压合并2型糖尿病引发的肾脏损伤	RAAS抑制剂
卡格列净	化药	上市：2型糖尿病，心力衰竭，DKD	SGLT2抑制剂
恩格列净	化药	上市：2型糖尿病，心力衰竭，慢性肾病	SGLT2抑制剂
非奈利酮	化药	上市：DKD，心力衰竭	盐皮质激素受体抑制剂
BI 685509	化药	Ⅱ期临床：糖尿病及其他慢性肾病	可溶性鸟苷酸环化酶（sGC）激动剂
BAY 3283142	化药	Ⅱ期临床：慢性肾病	可溶性鸟苷酸环化酶（sGC）激动剂
SK-08	化药	Ⅰ期临床：慢性肾病	可溶性鸟苷酸环化酶（sGC）激动剂
C66	化药	Ⅰ期临床：DKD	JNK1/2抑制剂
ZHC-116	化药	Ⅱ期临床：DKD	TGF-β1/SMAD抑制剂
硝酮嗪肠溶片	化药	Ⅱa期临床：DKD	清除自由基，保护线粒体功能，增加ATP产生，促进细胞自噬
SPH3127片	化药	Ⅱ期临床：DKD	肾素抑制剂
SC0062	化药	Ⅱ期临床：慢性肾病	高选择性内皮素受体A（ETA）拮抗剂
bremelanotide	化药	Ⅱb临床：DKD	黑素皮质素受体激动剂
LM49	化药	Ⅰ期临床：DKD	靶向PDIA6，调节IRE1α-XBP1/NF-κB
SZ2726片	化药	Ⅰ期临床：DKD	未公开
AP303片	化药	Ⅰ期临床：DKD	未公开
KBP-5074片	化药	Ⅲ临床：慢性肾病	非甾体类选择性盐皮质激素受体拮抗剂（MRA）
MY008211A片	化药	Ⅰ期临床：慢性肾病	补体因子B（CFB）抑制剂
脯氨酸恒格列净片	化药	Ⅲ期临床：慢性肾病	SGLT2抑制剂
WJ-39片	化药	Ⅰ期临床：DKD	醛糖还原酶抑制剂
UBT251	化药	Ⅱ期临床试验：慢性肾病	GLP-1R/GIPR/GCGR激动剂
注射用XTL6001	化药	Ⅰ期临床：慢性肾病	GLP-1R/GCGR/MasR三重靶点激动剂
司美格鲁肽	生物药	上市：2型糖尿病，体重管理，2型糖尿病合并慢性肾脏病	GLP-1激动剂
利拉鲁肽	生物药	上市：2型糖尿病，体重管理 Ⅲ期临床：慢性肾病	GLP-1激动剂
GMA131	生物药（单克隆抗体）	Ⅰ期临床：DKD	内皮素受体ETa的单克隆抗体
人脐带间充质干细胞注射液	生物药（干细胞）	Ⅰ期临床：DKD	抑制炎性反应、调节免疫功能
RYSW-01	生物药（干细胞）	Ⅱ期临床：慢性肾病	抑制炎性反应、调节免疫功能
RMCL-002	生物药（肾自体细胞）	Ⅱ期临床：慢性肾病	抑制炎性反应、调节免疫功能
渴络欣胶囊	中药复方	上市：DKD属气阴两虚兼夹血瘀证	益气养阴，活血化瘀
芪参益气滴丸	中药复方	上市：气血不足同时伴有血液流通不畅引发的胸闷胸痛，用于冠心病心绞痛及慢性心力衰竭 Ⅱ期临床：糖尿病肾脏疾病（气虚血瘀证）	益气通脉，活血止痛
黄蛭益肾胶囊	中药复方	上市：轻中度原发性普通型肾炎（气阴两虚或兼有血瘀症） Ⅱ期临床：糖尿病肾脏疾病	补气养阴，健脾益肾，化瘀利水
百令胶囊	中药复方	上市：慢性支气管炎、慢性肾功能不全的辅助治疗 Ⅱ期临床：糖尿病肾脏疾病（肺肾两虚证）	补肺肾，益精气
SZ1108片	中药	Ⅱ期临床：DKD	醛糖还原酶抑制剂
JMZ-2102胶囊	中药	Ⅰ期临床：慢性肾病	补肾秘精

药物名称	药品分类	适应症和研发阶段	作用靶点
厄贝沙坦	化药	上市：原发性高血压，高血压合并2型糖尿病引发的肾脏损伤	RAAS抑制剂
卡格列净	化药	上市：2型糖尿病，心力衰竭，DKD	SGLT2抑制剂
恩格列净	化药	上市：2型糖尿病，心力衰竭，慢性肾病	SGLT2抑制剂
非奈利酮	化药	上市：DKD，心力衰竭	盐皮质激素受体抑制剂
BI 685509	化药	Ⅱ期临床：糖尿病及其他慢性肾病	可溶性鸟苷酸环化酶（sGC）激动剂
BAY 3283142	化药	Ⅱ期临床：慢性肾病	可溶性鸟苷酸环化酶（sGC）激动剂
SK-08	化药	Ⅰ期临床：慢性肾病	可溶性鸟苷酸环化酶（sGC）激动剂
C66	化药	Ⅰ期临床：DKD	JNK1/2抑制剂
ZHC-116	化药	Ⅱ期临床：DKD	TGF-β1/SMAD抑制剂
硝酮嗪肠溶片	化药	Ⅱa期临床：DKD	清除自由基，保护线粒体功能，增加ATP产生，促进细胞自噬
SPH3127片	化药	Ⅱ期临床：DKD	肾素抑制剂
SC0062	化药	Ⅱ期临床：慢性肾病	高选择性内皮素受体A（ETA）拮抗剂
bremelanotide	化药	Ⅱb临床：DKD	黑素皮质素受体激动剂
LM49	化药	Ⅰ期临床：DKD	靶向PDIA6，调节IRE1α-XBP1/NF-κB
SZ2726片	化药	Ⅰ期临床：DKD	未公开
AP303片	化药	Ⅰ期临床：DKD	未公开
KBP-5074片	化药	Ⅲ临床：慢性肾病	非甾体类选择性盐皮质激素受体拮抗剂（MRA）
MY008211A片	化药	Ⅰ期临床：慢性肾病	补体因子B（CFB）抑制剂
脯氨酸恒格列净片	化药	Ⅲ期临床：慢性肾病	SGLT2抑制剂
WJ-39片	化药	Ⅰ期临床：DKD	醛糖还原酶抑制剂
UBT251	化药	Ⅱ期临床试验：慢性肾病	GLP-1R/GIPR/GCGR激动剂
注射用XTL6001	化药	Ⅰ期临床：慢性肾病	GLP-1R/GCGR/MasR三重靶点激动剂
司美格鲁肽	生物药	上市：2型糖尿病，体重管理，2型糖尿病合并慢性肾脏病	GLP-1激动剂
利拉鲁肽	生物药	上市：2型糖尿病，体重管理 Ⅲ期临床：慢性肾病	GLP-1激动剂
GMA131	生物药（单克隆抗体）	Ⅰ期临床：DKD	内皮素受体ETa的单克隆抗体
人脐带间充质干细胞注射液	生物药（干细胞）	Ⅰ期临床：DKD	抑制炎性反应、调节免疫功能
RYSW-01	生物药（干细胞）	Ⅱ期临床：慢性肾病	抑制炎性反应、调节免疫功能
RMCL-002	生物药（肾自体细胞）	Ⅱ期临床：慢性肾病	抑制炎性反应、调节免疫功能
渴络欣胶囊	中药复方	上市：DKD属气阴两虚兼夹血瘀证	益气养阴，活血化瘀
芪参益气滴丸	中药复方	上市：气血不足同时伴有血液流通不畅引发的胸闷胸痛，用于冠心病心绞痛及慢性心力衰竭 Ⅱ期临床：糖尿病肾脏疾病（气虚血瘀证）	益气通脉，活血止痛
黄蛭益肾胶囊	中药复方	上市：轻中度原发性普通型肾炎（气阴两虚或兼有血瘀症） Ⅱ期临床：糖尿病肾脏疾病	补气养阴，健脾益肾，化瘀利水
百令胶囊	中药复方	上市：慢性支气管炎、慢性肾功能不全的辅助治疗 Ⅱ期临床：糖尿病肾脏疾病（肺肾两虚证）	补肺肾，益精气
SZ1108片	中药	Ⅱ期临床：DKD	醛糖还原酶抑制剂
JMZ-2102胶囊	中药	Ⅰ期临床：慢性肾病	补肾秘精

[1]	Xin LIU, Xiaolin LIU, Yanan ZHOU, Jinguo ZHAI. New antipsychotic drug KarXT [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(3): 428-432.
[2]	Qing ZHANG, Panwei HU, Hua ZHOU. Animal model of intrauterine adhesions and its application in the treatment of intrauterine adhesions [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(2): 257-264.
[3]	Yayan SHI, Yu WANG, Wei KUANG, Shouyang YU. The latest progress in the pathogenesis of multiple sclerosis and drug therapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(1): 78-87.
[4]	JING Jiawen, MENG Qingbo, BI Zheng, WANG Fanjing, LI Yufan, FANG Zhaohui. Advances in animal models of diabetic erectile dysfunction based on therapeutic approaches [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(9): 1224-1232.
[5]	XU Linlin, ZHANG Dou, DING Pengtao, XI Xiaoxia, YANG Pengfei, ZHANG Xiaoya, LI Tingbao. Protective mechanism of Guomin decoction against atopic dermatitis in mice based on TLR4/MyD88/NF-κB signaling pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(12): 1648-1657.
[6]	REN Menghan, YAO Jianli, YANG Lixia, SHU Chang. Effect and mechanism of extracts from oxytropis falcata on improving oxidative damage of podocytes induced by high glucose via regulating PI3K/AKT/Nrf2 pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(10): 1361-1373.
[7]	BAI Xuechun, CHEN Shuo, LI Shanshan, LI Qinglin. Intervention study on the progress of subacute Parkinson's disease in mice with Kangzhen Zhijing spasmodic decoction Ⅰ [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2024, 29(6): 629-636.
[8]	ZHAO Zishuo, ZHU Yuguang, MA Yanshan, LI Zhiwei, JING Yongshuai, XIE Yinghua. Effects of different formulations of high-fat diet on establishment of a non-alcoholic fatty liver model in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2024, 29(5): 543-553.
[9]	XU Yiqi, WU Qian, LIU Shu, LIU Fan, XING Chunyan, LI Qin, HE Junjun, HE Chunling, ZHAO Yongli, GAO Jialin. Clinical efficacy and anti-inflammation/anti-fibrosis effect of tripterygium glycosides in the treatment of diabetic nephropathy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1034-1042.
[10]	CAO Zhiwen, HU Weihua. Effects of intrauterine perfusion of growth hormone on thin endometrium [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(9): 983-988.
[11]	ZHENG Qiongna, WU Qiaoqiao, MA Zhele, ZHANG Xianfei, GAN Fangmin, KONG Qingming. Interventional effect of low molecular weight heparin on mice with experimental hepatic fibrosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(5): 511-516.
[12]	LIU Jiangang, WANG Xiaobo. Expression and significance of TRPV1 and TRPA1 in DRG neurons of rats with endometriosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(6): 617-621.
[13]	ZHANG Wei-Jian, XU Jian-Hua, ZHANG Jie-Min, CHEN Jin-Mei, CHEN Xiu-Ying, YANG Mei-Chun, 吕Wen-Long , HONG Jin-Sheng. Build up acute radiation-induced lung injury model in mice and observe the protect effect of Glycyrrhetic acid [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(6): 629-633.
[14]	YANG Lin-cheng, HE Yi-lei, LI Wei-dong. Research advances of the leukemia animal models [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(12): 1416-1421.
[15]	LIU Xing, WANG Meng-ya. Improving effects of gastrodin on learning and memory in model rats with Alzheimer disease induced by intra-hippocampal Aβ_1-40 injection [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(4): 408-411.